Is Nivolumab reimbursable?

Nivolumab (Nivolumab) is indicated for the treatment of unresectable or metastatic melanoma, melanoma as adjuvant therapy, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classic Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial cancer, microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, hepatocellular carcinoma and esophageal cancer. The original drug nivolumab is currently on the market in China, but it has not yet been included in medical insurance, so it cannot be reimbursed by medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. The price of each box of 40mg/4ml may be around RMB 4,000.